The comparison of early gestational complications and perinatal outcomes of the pregnant women who used metoclopramide and dimenhydrinate. Perinatal Journal 2014;22(4):147-151
- Etlik Zübeyde Hanım Kadın Hastalıkları Eğitim ve Araştırma Hastanesi, İnfertilite Bölümü- Ankara TR
- Dr. Faruk Sükan Kadın Hastalıkları Doğum ve Çocuk Hastalıkları Hastanesi, Kadın Hastalıkları ve Doğum Kliniği- Konya TR
- Başkent Üniversitesi Tıp Fakültesi Aile Hekimliği Anabilim Dalı- Ankara TR
- Etlik Zübeyde Hanım Kadın Hastalıkları Eğitim ve Araştırma Hastanesi, Perinatoloji Bölümü- Ankara TR
Şafak Özdemirci, Etlik Zübeyde Hanım Kadın Hastalıkları Eğitim ve Araştırma Hastanesi, İnfertilite Bölümü- Ankara TR, [email protected]
Manuscript Received: January 17, 2014
Manuscript Accepted: March 17, 2014
Earlyview Date: August 01, 2014
Conflicts of Interest
No conflicts declared.
Metoclopramide and dimenhydrinate are used commonly in the treatment of nausea-emesis and hyperemesis gravidarum during the first trimester.
This retrospective study included 233 pregnant women who were diagnosed as hyperemesis gravidarum during first trimester between July 4, 2005 and May 27, 2009 at the Clinic of Obstetrics and Gynecology, Simav State Hospital (Simav, Kütahya, Turkey). The pregnant women were separated into groups according to their metoclopramide or dimenhydrinate use. The pregnant women included in the study were chosen from the pregnant women who were healthy and had singleton pregnancy.
While 113 pregnant women were treated by metoclopramide and 120 pregnant women by dimenhydrinate. Spontaneous abortion was found as 6.2% in the pregnant women who used metoclopramide and as 4.2% who used dimenhydrinate, and stillbirth rate was 1.8 and 0.8%, respectively. Low birth weight rates were 8.0% in metoclopramide group and 5.8% in dimenhydrinate group, and preterm labor rates were 5.3% and 5.0%, respectively.
We have found that there was no difference between the pregnant women who used metoclopramide and dimenhydrinate in terms of early period complications and perinatal outcomes.
Nausea, emesis, pregnancy, first trimester.
Nausea and emesis are common complaints seen during pregnancy. They are seen in approximately 80% of pregnant women. Hyperemesis gravidum (HG) is defined as severe nausea and emesis during pregnancy. Since it is a severe and resistive condition resulting in ketosis, dehydration and loss of weight, it is differed from nausea and emesis during regular pregnancy.[2,3] The frequency of hyperemesis gravidum is between 0.3% and 10% in pregnancies.[4,5]
If not treated, serious complications may arise in mother due to severe emesis such as dehydration, disorder in electrolyte-fluid balance, significant loss of weight, Wernicke's encephalopathy, renal failure, hepatic function disorder and secondary depressions.[3,4,6]
Doxylamine, pyridoxine, antihistamines, H1 receptor blockers and phenothiazines are all reliable and effective drugs for slight, mild and severe nausea and emesis during pregnancy.[4,7]
In Australia, methoclopramide is the first choice for hyperemesis gravidarum treatment, and methoclopramide is prescribed to 86% of pregnant women. Intravenous rehydration and thiamine may be needed together with antiemetic drugs (doxylamine, methoclopramide and chlorpromazine) in the treatment of hyperemesis gravidarum.[4,9]
In our study, we studied whether there is difference between early period complications and perinatal outcomes of pregnant women who were treated with methoclopramide and dimenhydrinate during first trimester.
As the study group, the medical files of 233 pregnant women were analyzed retrospectively who admitted to the Clinic of Obstetrics and Gynecology, Simav State Hospital between July 4, 2005 and May 27, 2009, had nausea and emesis, could not nourished orally, found to be positive for ketone in the urine analysis, and treated by methoclopramide and dimenhydrinate. The study groups consisted of the pregnant women who used methoclopramide and dimenhydrinate.
The women who had nausea and emesis during 6-12 weeks of gestation, needed medical treatment and had singleton intrauterine pregnancy were included in the study. Since fetal and maternal results would be affected, those who had kin marriage, habitual abortion, cervical insufficiency, pregnant women who miscarried voluntarily, molar pregnancies, those who had labor history with fetal anomaly in their previous pregnancy, those established with the diagnosis of preeclampsia, spontaneous preterm labor risk, hyperthyroidism, gastroenteritis, hepatitis and urinary tract infection, those who had psychiatric therapy, had an underlying medical disease and those not married were excluded from the study. The pregnant women who were included in the study were not smoking, drinking alcohol or using narcotic drugs. All pregnant women staying in the hospital were applied routinely hemogram, biochemical tests, urine analysis, Hepatitis B virus surface antigen, free T4, TSH and ultrasound examination. In the ultrasound examination, singleton pregnancy with positive fetal cardiac activity between 6 and 12 weeks of gestation according to CRL was observed. Also, general obstetric ultrasonography was carried out for major anomaly screening between 20 and 22 weeks of gestation.
Abortion was defined as stillbirth for fetuses under 20 weeks or below 500 g, and intrauterine fetal death was defined as deliveries after 200 weeks or above 500 g with no fetal cardiac activity at intrauterine period. Low birth weight was described as the births below 2500 g and those born before 37 weeks of gestation were defined as premature labor. Pregnancy-induced hypertension was described as the condition for pregnant women who have arterial blood pressure at and above 140/90 mg at 20 weeks of gestation.
The pregnant women hospitalized in the clinic for pregnancy nausea-emesis and HG were had rehydration treatment by 0.9% NaCl and 10% dextrose solution.[3,5,6,9] Vitamin complex (Bemiks C) was applied by intravenous administration once a day. Dimenhydrinate and metoclopramide were used in the treatment since they are widely used in the treatment of nausea and emesis during pregnancy,[1,3] reliable,[2,4] effective, cost-efficient and easily accessible. Dimenhydrinate[15,16] 50 mg was administered intravenously twice a day and metoclopramide[2,17,18] 5 mg ampoule intravenously four times daily.
The pregnant women were discharged by being prescribed oral tablets of the drugs administered parenterally to take them at home as 7-10 days treatment.
In the statistical analysis, definitive test, Student-t test, chi-squared test and Fisher’s exact test were used for the comparison of two groups. A p value <0.05 was considered significant statistically.
The medical files of 233 pregnant women, who were treated by metoclopramide and dimenhydrinate for pregnancy nausea-emesis or HG in the first trimester, were analyzed retrospectively. It was found that 113 pregnant women used metoclopramide and 120 pregnant women used dimenhydrinate. There was statistically no significant difference between two groups in terms of mean ages of the pregnant women and birth weights of their babies (Table 1). The rate of spontaneous abortion was 6.2% (n=7) in the group treated by metoclopramide, and 4.2% (n=5) in the group treated by dimenhydrinate (p=0.484). In both groups, spontaneous abortion occurred after 8 weeks of gestation. We found the rate of intrauterine fetal death (IUFD) as 1.8% (n=2) in the pregnant women using metoclopramide and as 0.8% (n=1) in the pregnant women using dimenhydrinate (p=0.62). Low birth weight was found as 8% (n=9) in the pregnant women using metoclopramide and as 5.8% (n=7) in the pregnant women using dimenhydrinate (p=0.52). The preterm labor rate was 5.3% (n=6) in those treated by metoclopramide and 5.0% (n=6) in those treated by dimenhydrinate (p=0.58). Fetal anomaly rate was 2.7% (n=3) in metoclopramide group and 2.5% (n=3) in dimenhydrinate group, and there was statistically no significant difference between the groups (p=0.91). For both groups, there was no statistical difference between early period gestational complications and perinatal gestational outcomes (Table 2).
We have compared early period complications and perinatal outcomes of two groups consisted of the pregnant women having nausea and emesis or diagnosed as HG and treated either by metoclopramide or dimenhydrinate. We have found that there was statistically no difference between the rates of abortion, intrauterine death, premature labor, low birth weight, fetal anomaly and pregnancy-induced hypertensive diseases.
In all pregnant women, abortion rate after 8 weeks of gestation varies between 3.2% and 6%.[10,19,20] We have found that there was no statistical difference between the abortion rates (6.2% and 4.2%) of those treated by metoclopramide and dimenhydrinate. At the same time, observing same abortion rate in the general pregnancy population has made us to consider that both drugs have no effect on abortion.
In the literature, there are publications reporting that there is no relationship between HG and IUFD.[21-23] In two studies carried out, it was reported that there was no increase in IUFD risk in the pregnant women treated by metoclopramide.[18,22] In the study published by Matok et al. in 2009, metoclopramide was used during the first trimester in 3458 pregnant women and perinatal death rate was found as 1.5% in those treated by metoclopramide and as 2.2% in the control group. It was reported that metoclopramide did not cause any increase in perinatal death rate. In our study, we found the IUFD rate as 1.8% in metoclopramide group and as 0.8% in dimenhydrinate group. The findings of our study are similar to other studies and we determined that both drugs did not cause any change in IUFD rate.
We have found the rate of low birth weight as 8.0% and 5.8% in metoclopramide and dimenhydrinate groups, and there was statistically no significant difference between the groups. There are publications in the literature providing different findings between low birth weight and pregnant women having antiemetic treatment.[24,25] In some studies, it has been reported that antiemetic drugs may cause low birth weight.[2,21,26] In another study, it was concluded that there was no increase in the risk of low birth weight by antiemetic drugs. In two studies, the relationship between pregnant women treated by metoclopramide and control group not used any drug was analyzed in terms of low birth weight, and it was concluded that there was no increase in the risk of low birth weight by metoclopramide.[17,18] However, in the studies of Mullin et al., Dodds et al. and Bailit et al., it was reported that HG caused low birth weight.[6,23,28] In the study of Mullin et al., it was stated that nausea and emesis of pregnant women continued even after 27 weeks of gestation. Dodds et al. included pregnant women whose nausea and emesis continued up to 24 weeks of gestation into their study group. In their study, they reported that low birth weight increased in pregnant women with HG who gained weight less than 7 kg totally during pregnancy. In our study group, the nausea and emesis of pregnant women did not continue after 14 weeks of gestation. The emesis duration and weight gaining are different in the literature[6,27] than our study. In other studies of the literature, it was reported that HG did not cause low birth weight.[25,28,29] In our study, we have found that there was no difference among the groups in terms of the rates of newborns with low birth weight.
The preterm labor rate was 5.3% in the group treated by metoclopramide and 5.0% in the group treated by dimenhydrinate. There was statistically no significant difference between the groups.
In the literature, there are various data on preterm labor and the role of HG. Czeizel and Puho and Klebanoff et al. showed in their studies that preterm labor risk decreased. Hallak et al. and Depue et al. reported in their studies that HG had no impact on premature labor. Dodds et al. reported in their studies on HG published in 2006 that the preterm labor risk increased in pregnant women who gained weight less than 7 kg during pregnancy, but preterm risk did not increase in pregnant women who gained weight more than 7 kg. While premature birth rate in pregnants using metoclopramide for HG treatment during first trimester was 5.8%, it was found as 6.0% in the control group who used no drug. Matok et al. found premature labor rate as 6.3% in metoclopramide group and as 5.9% in the control group. It was reported that metoclopramide has no impact on premature labor.[15,17,18] In other publications, it was stated that premature labor risk was not increased.[29,30] In our study group, there were no pregnant women who have smoking, alcohol and drug addiction. Also, it was seen that gestational follow-ups were made regularly. Although there is no difference between the groups in terms of preterm labor rate, we found similar rates compared to other publications in the literature.[15,17,18,29,30]
Antihistaminic drugs block the receptor in the nausea center of vestibular system. After histamine 1 receptor is blocked, the stimulation of nausea center decreases. Dimenhydrinate is widely used in pregnant women in North America. By many epidemiological studies, it was found that dimenhydrinate has no teratogenic impact on human fetuses. In animal trials carried out by antihistaminic drugs, it was found that they are teratogenic; however, it was used in the treatment of more than 200.000 pregnants as of 1950 and reported to be non-teratogenic on human fetuses. In the same study, anomaly was observed in 1-3% of the babies of pregnant women who used antihistaminic drugs. Czeziel and Vargha reported in their case-control study that there was no increase in congenital anomalies of fetuses of the pregnant women who were treated by dimenhydrinate during their pregnancies. In a large scaled research study carried out between 2000 and 2004, it was shown that using antihistaminic drug in the treatment of nausea and emesis during pregnancy is safe. Metoclopramide is in group A among the safety categories for pregnancy. Sorensen et al. treated 309 pregnant women with hyperemesis by metoclopramide during first trimester. They found fetal anomaly in 5.8% of treated pregnant women and in 5.2% of control group, and reported that metoclopramide did not cause any fetal anomaly. In the research study performed by Matok et al., it was found that there was no difference between the pregnant women who used metoclopramide and the control group in terms of fetal anomaly.
In our study, we did not find any difference between pregnancy groups treated by metoclopramide and dimenhydrinate in terms of the rates of pregnancy-induced hypertensive diseases. The study of Kuru et al. showed no relationship between HG and pregnancy-induced hypertensive diseases. In another study, it was reported that hyperemesis gravidarum seen during the first trimester slightly increased preeclampsia risk; however, HG seen during the second trimester had a strong relationship with placental dysfunction diseases.
It is known that severe complications occur if severe HG is not treated. Antiemetic drugs are widely used in order to prevent complications that may appear in mother. There is no difference between using metoclopramide and dimenhydrinate during first trimester in terms of gestational outcomes.
Conflicts of Interest: No conflicts declared.
1. Macle L, Varlet MN, Cathébras P. A rare but potentially severe complication of the first trimester of pregnancy. Rev Prat 2010;60:759-64.
2. Seehan P. Hyperemesis gravidarum--assessment and management. Aust Fam Physician 2007;36:698-701.
3. Spiegel DR, Webb K. A case of treatment refractory hyperemesis gravidarum in a patient with comorbid anxiety, treated successfully with adjunctive gabapentin: a review and the potential role of neurogastroentereology in understanding its pathogenesis and treatment. Innov Clin Neurosci 2012;9: 31-8.
4. Bsat FA, Hoffman DE, Seubert BA E. Comprasion of three outpatient regimens in the management of nauseas and vomiting in pregnancy. J Perinatol 2003;23:531-5.
5. Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. J Obstet Gyneacol 2004;24:530-3.
6. Mullin PM, Ching C, Schoenberg F, MacGibbon K, Romero R, Goodwin TM, et al. Risk factors, treatments, and outcomes associated with prolonged hyperemesis gravidarum. J Matern Fetal Neonatal Med 2012;25:632-6.
7. Magee LA, Mazzotto P. Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy. Am J Obstet Gynecol 2002;186(5 Suppl Understanding):S256-61.
8. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gyneacol 2013;53:358-62.
9. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol 2001;41:842-5.
10. Pasternak B, Svanström A, Hviid A.Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013;368:814-23.
11. Robalo R, Pedroso C, Amaral N, Soares C. Late stillbirth: a ten year cohort study. Acta Med Port 2013;26:39-42.
12. Jancevska A, Tasic V, Damcevski N, Danilovski D, Jovanovska V, Gucev Z. Children born small for gestational age (SGA). Prilozi 2012;33:47-58.
13. Smith GC, Pell JP. Teenage pregnancy and risk adverse perinatal outcomes associated with first and second births: population based retrospective cohort study. BMJ 2001;323 (7311):476.
14. Stuart JJ, Bairey Merz CN, Berga SL, Miller VM, Ouyang P, Shufelt CL, et al. Maternal recall of hypertensive disorders in pregnancy: a systematic review. J Womens Health (Larchmt). 2013 ;22(1):37-47
15. Lee J, Einarson A, Gallo M, Okotore B, Koren G. Longitudinal change in the treatment of nausea and vomiting of pregnancy in Ontario. Can J Clin Pharmacol 2000;7: 205-8.
16. Czeizel AE, Vargha P. A case-control study of congenital abnormality and dimenhydrinate usage during pregnancy. Arch Gynecol Obstet 2005;271:113-8.
17. Sørensen HT1, Nielsen GL, Christensen K, Tage-Jensen U, Ekbom A, Baron J. Birth outcome following maternal use of metoclopramide. The Euromap study group. Br J Clin Pharmacol 2000;49:264-8.
18. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:2528-35.
19. Hill LM, Guzick D, Fries J, Hixson J. Fetal loss rate after ultrasonically documented cardiac activity between 6 and 14 weeks, menstrual age. J Clin Ultrasound 1991;19:221-3.
20. Simpson JL, Mills JL, Holmes LB, Ober CL, Aarons J, Jovanovic L, et al. Low fetal loss rates after ultrasound-proved viability in early pregnancy. JAMA 1987;258:2555-7.
21. Weigel MM, Weigel RM. Nausea and vomiting of early pregnancy and pregnancy outcome. An epidemiological study. Br. J Obstet Gynaecol. 1989;96:1304-11.
22. Hallak M, Tsalamandris K, Dombrowski MP, Isada NB, Pryde PG, Evans MI. Hyperemesis gravidarum. Effects on fetal outcome. J Reprod Med 1996;41:871-4.
23. Dodds L, Fell DB, Joseph KS, Allen VM, Butler B. Outcomes of pregnancies complicated with hyperemesis gravidarum. Obstet Gynecol 2006;107:285-92
24. Leathem AM. Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. Clin Pharm 1986;5:660-8.
25. Czeizel AE, Puho E. Association between severe nausea and vomiting in pregnancy and lower rate of preterm births. Paediatr Perinat Epidemiol 2004;18:253-9.
26. Veenendaal MV, van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG 2011;118:1302-13.
27. Kuru O, Sen S, Akbayır O, Goksedef BP, Ozsürmeli M, Attar E, et al. Outcomes of pregnancies complicated by hyperemesis gravidarum. Arch Gynecol Obstet 2012;285:1517-21.
28. Bailit JL. Hyperemesis gravidarum: epidemiologic finding from a large cohort. Am J Obstet Gynecol 2005;193:811-4.
29. Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. Obstet Gynecol 1985;66:612-6.
30. Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am J Obstet Gynecol 1987;156:1137-41.
31. Seto A, Einarson T, Koren G. Pregnancy outcome fallowing first trimester exposure to an antihistamines: meta-analysis. Am J Perinatol 1997;14:119-24.
32. Goodwin TM, Poursharif B, Korst LM, MacGibbon KW, Romero R, Fejzo MS. Secular trends in the treatment of hyperemesis gravidarum. Am J Perinatol 2008;25:141-7.
33. Bolin M, Åkerud H, Cnattingius S, Stephansson O, Wikström AK. Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOB 2013;120:541-7.
Distribution of maternal age and birth weights.
Early period gestational complications and perinatal outcomes
of control and study groups.